Cargando…

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

BACKGROUND: Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugano, Teppei, Seike, Masahiro, Saito, Yoshinobu, Kashiwada, Takeru, Terasaki, Yasuhiro, Takano, Natsuki, Hisakane, Kakeru, Takahashi, Satoshi, Tanaka, Toru, Takeuchi, Susumu, Miyanaga, Akihiko, Minegishi, Yuji, Noro, Rintaro, Kubota, Kaoru, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113045/ https://www.ncbi.nlm.nih.gov/pubmed/32096610 http://dx.doi.org/10.1111/1759-7714.13364

Ejemplares similares

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
por: Tozuka, Takehiro, et al.
Publicado: (2018)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
por: Hisakane, Kakeru, et al.
Publicado: (2021)

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
por: Matsumoto, Masaru, et al.
Publicado: (2015)

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
por: NISHIJIMA, NOBUHIKO, et al.
Publicado: (2016)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato, Yuki, et al.
Publicado: (2021)

Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
por: Hayashi, Anna, et al.
Publicado: (2022)

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
por: Sugano, Teppei, et al.
Publicado: (2019)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
por: Tozuka, Takehiro, et al.
Publicado: (2023)

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
por: Fukuizumi, Aya, et al.
Publicado: (2015)

The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non‐small cell lung cancer
por: Shimizu, Masamitsu, et al.
Publicado: (2022)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Takahashi, Akiko, et al.
Publicado: (2018)

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
por: Nakamichi, Shinji, et al.
Publicado: (2018)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B
por: Noro, Rintaro, et al.
Publicado: (2020)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
por: Iso, Hirokazu, et al.
Publicado: (2023)

CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
por: Fukuizumi, Aya, et al.
Publicado: (2021)

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
por: Misawa, Kazuhito, et al.
Publicado: (2023)

Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination
por: Kashiwada, Takeru, et al.
Publicado: (2022)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
por: Takeuchi, Susumu, et al.
Publicado: (2023)

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
por: Takahashi, Satoshi, et al.
Publicado: (2021)

Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations
por: Aoyama, Junichi, et al.
Publicado: (2019)

Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban
por: Naito, Tomoyuki, et al.
Publicado: (2018)

Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma
por: IIJIMA, YOSHIHITO, et al.
Publicado: (2014)

Acute respiratory failure due to Aspergillus niger infection with acute fibrinous and organazing pneumonia: A case report
por: Okamura, Ken, et al.
Publicado: (2022)

MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
por: CAO, MENGRU, et al.
Publicado: (2012)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review
por: Suzuki, Ayana, et al.
Publicado: (2023)

Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
por: Gemma, Akihiko, et al.
Publicado: (2006)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma
por: Mikami, Erika, et al.
Publicado: (2023)

Alpha‐actinin‐4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas
por: Noro, Rintaro, et al.
Publicado: (2022)

Pulmonary manifestation of inflammatory bowel disease: Two case reports
por: Suzuki, Ayana, et al.
Publicado: (2023)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial
por: Horinouchi, Hidehito, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_66khaqimnqhidagvkgu5mhou3b